Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Core Insights - Silo Pharma, Inc. has launched a cryptocurrency treasury strategy focusing on leading digital assets such as Bitcoin, Ethereum, and Solana, aiming for opportunistic purchases and yield generation through staking while prioritizing capital preservation and token appreciation [1][2] - The company has appointed Corwin Yu, a seasoned technology and trading executive, as the head of its newly formed Crypto Advisory Board to lead this strategy [2] - Silo Pharma remains committed to its biopharmaceutical enterprise, particularly its lead asset, PTSD drug SPC-15, which is nearing the submission of an FDA investigational new drug application [3] Company Strategy - The cryptocurrency treasury strategy is expected to expand based on available capital and market conditions, indicating a flexible approach to digital asset investment [1] - The appointment of Corwin Yu is seen as a strategic move to leverage his extensive experience in cryptocurrency trading infrastructure and fund management [2] - The company is focused on innovative therapeutics for underserved conditions, with a diverse portfolio that includes programs targeting PTSD, fibromyalgia, Alzheimer's disease, and multiple sclerosis [3] Leadership and Expertise - Corwin Yu brings over 20 years of experience in institutional finance, having held leadership roles in various fintech and digital asset firms, which positions him well to guide Silo's cryptocurrency strategy [2] - His background includes founding and scaling digital asset trading platforms and overseeing cross-asset trading strategies, which will be beneficial for Silo's new initiatives [2] Commitment to Core Business - Despite the new focus on digital assets, Silo Pharma emphasizes its dedication to developing therapeutics for conditions like stress-induced psychiatric disorders and chronic pain [3] - The company is actively conducting research in collaboration with leading universities and laboratories to advance its therapeutic programs [3]